Literature DB >> 3261106

Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features.

P Tran Ba Huy1, D Deffrennes.   

Abstract

The influence of dosage regimen on gentamicin uptake by the inner ear tissues was investigated by radioimmunoassay in rat given single i.m. 10 or 100 mg/kg injection or i.v. 1.5 or 15 micrograms/min constant infusion. Results show that, for a given dose, discontinuous administration yields markedly lower tissue concentration than continuous administration and, thus, carries less ototoxic risk. Using 125I-labelled gentamicin as a radioligand correlation between membrane binding and clinical features was also studied in homogenates of organ of Corti and vestibular maculae of guinea-pig. Results show that: (i) as compared by Kd values, gentamicin exhibits a four-fold greater affinity for vestibule (Kd = 3 X 10(-7) M) than for cochlea (Kd = 1.2 X 10(-6) M). This explains the predilection of this antibiotic to affect the vestibular apparatus; (ii) the typical baso-lateral progression of ototoxic degeneration cannot be accounted for by a preferential uptake of the drug between base and apex.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261106     DOI: 10.3109/00016488809119511

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  10 in total

1.  [Transtympanic administration of gentamicin in Menière diseases--less is more!?].

Authors:  A Koitschev
Journal:  HNO       Date:  2003-11       Impact factor: 1.284

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

4.  Kill kinetics and regrowth patterns of Pseudomonas aeruginosa exposed to concentration-time profiles of tobramycin simulating in vivo infusion and bolus dosing.

Authors:  P J Wood; L L Ioannides-Demos; E B Bastone; W J Spicer; A J McLean
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 5.  Aminoglycoside therapy. Current use and future prospects.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

Review 6.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

7.  The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis.

Authors:  Angela C Garinis; Campbell P Cross; Priya Srikanth; Kelly Carroll; M Patrick Feeney; Douglas H Keefe; Lisa L Hunter; Daniel B Putterman; David M Cohen; Jeffrey A Gold; Peter S Steyger
Journal:  J Cyst Fibros       Date:  2017-02-24       Impact factor: 5.482

8.  Gentamicin pharmacokinetics in the chicken inner ear.

Authors:  Eric C Bunting; Debra L Park; Dianne Durham; Douglas A Girod
Journal:  J Assoc Res Otolaryngol       Date:  2004-06

9.  Gentamicin-induced alterations of succinic dehydrogenase activity in the organ of Corti as revealed by non-decalcified frozen sections of the guinea pig's cochlea.

Authors:  F S Yang; J S Han
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

10.  Wideband Acoustic Reflex Growth in Adults With Cystic Fibrosis.

Authors:  Martha R Westman; Daniel B Putterman; Angela C Garinis; Lisa L Hunter; M Patrick Feeney
Journal:  Am J Audiol       Date:  2021-03-04       Impact factor: 1.636

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.